Related Experiment Video

Updated: Aug 19, 2026

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

Genetics and variability in opioid response

Ulrike M Stamer1, Bettina Bayerer, Frank Stüber

  • 1Department of Anaesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms-Universität Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany. ulrike.stamer@ukb.uni-bonn.de

European Journal of Pain (London, England)
|March 2, 2005
PubMed

Insights

Genetic variations impact how well pain medications like opioids work. Understanding these genetic differences can help tailor treatments for better pain management and fewer side effects.

Area of Science:

  • Pharmacogenomics
  • Genetics
  • Pain Management

Background:

  • The Human Genome Project identified genomic variations influencing drug responses.
  • Genetic factors significantly affect opioid therapy efficacy in pain management.
  • Variations in drug-metabolizing enzymes, like CYP2D6, are linked to adverse drug reactions and healthcare costs.

Purpose of the Study:

  • To investigate the role of genetic variability in pain therapy.
  • To explore how genetic differences influence the efficacy and safety of pharmacotherapy.
  • To identify candidate genes affecting pain perception, processing, and management.

Main Methods:

  • Screening for variations in drug-metabolizing enzyme expression.
  • Investigating candidate genes including opioid receptors and transporters.
  • Analyzing genetic differences related to pharmacotherapy outcomes.

Main Results:

  • CYP2D6 genetic variability is a significant factor in adverse drug reactions.
  • Genetic background influences opioid therapy efficacy.
  • Ongoing research targets genes involved in pain pathways and drug targets.

Conclusions:

  • Understanding genetic differences is crucial for optimizing pain management.
  • Pharmacogenomic screening can improve patient therapy and reduce healthcare costs.
  • Future pain management strategies will increasingly incorporate genetic insights for personalized treatment.

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...